Finland · Biotechnology
Finland · BiotechnologyHerantis Pharma
Herantis Pharma A pharmaceutical company targeting unmet clinical needs.
PublicFor profit
Against its peers
Set against 66 Biotechnology companies in Finland. The ring marks the typical peer.
Across all 5.9M companies: larger than 33% of those with a size listed; older than 40% of those with a founding year; website ranked #13,775,183 in the world, about 72 visits a month. 23 people list it on LinkedIn, and 4,818 follow it.
About Herantis Pharma
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’s lead product, HER-096 is a first-in-class agent in development for the treatment of Parkinson’s disease with disease modifying potential and convenient subcutaneous administration. Primary objective of the ongoing Phase 1b clinical trial is to assess the safety, tolerability and pharmacokinetics of repeated subcutaneous doses of HER-096; the trial will also evaluate selected… Read all
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’s lead product, HER-096 is a first-in-class agent in development for the treatment of Parkinson’s disease with disease modifying potential and convenient subcutaneous administration. Primary objective of the ongoing Phase 1b clinical trial is to assess the safety, tolerability and pharmacokinetics of repeated subcutaneous doses of HER-096; the trial will also evaluate selected biomarkers and monitor symptoms associated with Parkinson’s disease. Topline data from Phase 1b trial is expected in September 2025. The Phase 1b trial is funded by the Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Parkinson’s Virtual Biotech. Herantis is listed on the Nasdaq First North Growth Market Finland.
BiotechnologyClinical TrialsPharmaceuticalParkinson's diseaseNeurodegenerative diseasesBiologicsbiotechdrug development
Funding, as listed
What the source datasets report. We have not watched these rounds ourselves, and do not hold this company in the startups database.
$23M
raised in total across 9 rounds
Last raised Jul 2024, 2 years ago
- Rounds
- 9
- Latest round
- Grant
- Latest amount
- $5.4M
- Investors
- 43 leading
Key facts
Who started it and how it trades.
- Founded by
- Henri Huttunen
Every detail we hold
Everything the source datasets list about Herantis Pharma, field by field. Contact details are held but never shown.
The company8 fields
- Name
- Herantis Pharma
- Type
- For profit
- Status
- Public
- Founded
- 2008
- Founders
- Henri Huttunen
- Industry
- Biotechnology
- Categories
- Biotechnology, Clinical Trials, Pharmaceutical
- Specialities
- Parkinson's disease, Neurodegenerative diseases, Biologics, biotech, drug development
Where4 fields
- City
- Espoo
- Region
- Southern Finland
- Country
- Finland
- Markets
- European Union (EU), Nordic Countries, Scandinavia, Europe, Middle East, and Africa (EMEA)
Size and reach5 fields
- Staff band
- 11-50
- People on LinkedIn
- 23
- LinkedIn followers
- 4,818
- Web traffic rank
- #13,775,183
- Monthly web visits
- 72
Show 10 more fieldsShow fewer fields
Funding, as listed8 fields
- Total
- $22,608,481 USD
- Rounds
- 9
- Latest round
- Grant
- Latest round date
- Jul 2024
- Latest amount
- 5,407,451 USD
- Investors
- 4
- Lead investors
- 3
- Listing status
- public
About this record2 fields
- Sources
- Crunchbase, LinkedIn
- Last imported
- Sept 2026
Growth, as the source summarises it
Herantis Pharma may be growing as indicated by several financial activities. The company has announced an invitation to its full year 2023 results webcast, which suggests that they are prepared to share financial results with stakeholders, potentially reflecting positive performance. Additionally, Herantis Pharma has registered 2.147.710 new shares in the trade register, which could imply a successful capital increase, often associated with expansion and growth strategies. The registration of new shares typically indicates an infusion of new equity capital, which can be used to fund research, development, and other growth-related activities.
Companies like Herantis Pharma
Biotechnology in Finland.
Onego BioHelsinki · 11-50 peoplefounded 14 years later
EniferEspoo · 11-50 peoplefounded 12 years later
Green Fuel Nordic OyLieksa · 1-10 peoplefounded 3 years later
CH-Bioforce OyEspoo · 1-10 peoplefounded 8 years later
Aurealis TherapeuticsKuopiosmaller: 3k followers
Oncos Therapeutics11-50 peoplesmaller: 272 followersBuild a lead list
66 Biotechnology companies in Finland, filtered by size, age and reach, ready to export with emails on Pro.